Pain Therapeutics Announces Investor Call to Provide Strategic Update
03 Octobre 2018 - 1:48AM
Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical
company, today announced that it will host a live conference call
to provide a strategic update regarding its business, its science
and its pipeline. The call is scheduled to be held Thursday,
October 4th at 10 AM Eastern time, 9 AM Central time.
The audio presentation will be available via
teleconference, which can be accessed by dialing (877) 407-4018 or
(201) 689-8471 for international callers. A toll-free replay
will be available at (844) 512-2921, or (412) 317-6671 for
international callers, using the conference ID code: 13683822
The Company’s presentation will be available
live via webcast and conference call. To listen to the webcast and
view the accompanying slide presentation, please go to the
Company’s website at http://www.paintrials.com/ and click on the
webcast icon at least 15 minutes before the presentation is to
begin to register. If you are unable to listen to the live
webcast, please access http://www.paintrials.com/ at any time
within seven days to listen to a replay of the webcast.
About Pain
Therapeutics, Inc.Pain Therapeutics, Inc. is a
clinical-stage biopharmaceutical company that develops novel
drugs. The Company believes its research program in
Alzheimer’s disease has game-changing characteristics. Its
lead drug candidate, PTI-125, is a small molecule with a unique
mechanism of action to treat Alzheimer’s disease. The
underlying science for PTI-125 is published in prestigious
peer-reviewed journals, including Journal of Neuroscience,
Neurobiology of Aging, and Neuroimmunology and Neuroinflammation,
and benefits from several peer-reviewed research grant awards from
the National Institutes of Health (NIH).
The Company is also developing a blood test,
called PTI-125DX, to detect Alzheimer’s disease, possibly years
before symptoms appear. An early diagnosis of Alzheimer's
could allow treatment to start sooner, optimize treatment options
for each individual and improve chances to slow or halt the
disease.
Last, the Company also has an NDA-stage drug
asset, REMOXY, for severe chronic pain, which is currently held up
at the U.S. Food and Drug Administration (FDA). The FDA has
not yet established the safety or efficacy of any of our drug
candidates. For more information, please visit
www.paintrials.com.
Note Regarding Forward-Looking
Statements: This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Pain Therapeutics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such statements
include, but are not limited to, statements regarding the potential
benefits of the Company’s program in Alzheimer’s disease.
Such statements are based on management's current expectations, but
actual results may differ materially due to various factors.
Such statements involve risks and uncertainties, including, but not
limited to, those risks and uncertainties relating to our financial
and operational ability to carry out development activities around
Alzheimer’s disease. For further information regarding these
and other risks related to our business, investors should consult
our filings with the U.S. Securities and Exchange Commission.
For More Information
Contact:Ruth ArayaPain Therapeutics,
Inc.IR@paintrials.com(512) 501-2485
Pain Therapeutics (NASDAQ:PTIE)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Pain Therapeutics (NASDAQ:PTIE)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024